Abstract: A system for isolating a target molecule from a bioprocess fluid includes a single-use disposable separation device having a plurality of perimeter-bonded layers defining one or more mesofluidic channels of the separation device, wherein each layer includes a biocompatible polymer material, wherein the separation device is configured to separate at least a portion of particles from the bioprocess fluid to generate a substantially clarified bioprocess fluid, and a chromatography system fluidically coupled at the outflow of the separation device in a configuration for further processing the clarified bioprocess fluid.

Abstract: A system for isolating a target molecule from a bioprocess fluid includes a single-use disposable separation device having a plurality of perimeter-bonded layers defining one or more mesofluidic channels of the separation device, wherein each layer includes a biocompatible polymer material, wherein the separation device is configured to separate at least a portion of particles from the bioprocess fluid to generate a substantially clarified bioprocess fluid, and a chromatography system fluidically coupled at the outflow of the separation device in a configuration for further processing the clarified bioprocess fluid.

Abstract: The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed.

Abstract: The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed.

Abstract: The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed.

Abstract: A system for isolating a target molecule from a bioprocess fluid includes a single-use disposable separation device having a plurality of perimeter-bonded layers defining one or more mesofluidic channels of the separation device, wherein each layer includes a biocompatible polymer material, wherein the separation device is configured to separate at least a portion of particles from the bioprocess fluid to generate a substantially clarified bioprocess fluid, and a chromatography system fluidically coupled at the outflow of the separation device in a configuration for further processing the clarified bioprocess fluid.

Abstract: A separation device, system and associated method are provided herein for separation of particulates form a base fluid. The separation device comprises a first microchannel comprising a fluid inlet and a mesofluidic collection chamber. The mesofluidic collection chamber has a first side and a second side, wherein the mesofluidic collection chamber is operatively coupled to the first microchannel on the first side, and wherein the mesofluidic collection chamber comprises a first fluid outlet at the second side, such that the fluid inlet, first microchannel, and first fluid outlet are in fluidic communication via the mesofluidic collection chamber.

Abstract: The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed.

Abstract: The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed.

Abstract: A separation device, system and associated method are provided herein for separation of particulates form a base fluid. The separation device comprises a first microchannel comprising a fluid inlet and a mesofluidic collection chamber. The mesofluidic collection chamber has a first side and a second side, wherein the mesofluidic collection chamber is operatively coupled to the first microchannel on the first side, and wherein the mesofluidic collection chamber comprises a first fluid outlet at the second side, such that the fluid inlet, first microchannel, and first fluid outlet are in fluidic communication via the mesofluidic collection chamber.

Abstract: The present disclosure relates to a composition of albumin microbubbles to which are bound one or more moieties that exhibit a binding preference for the albumin microbubbles relative to free, native HSA. Production of the albumin microbubble composition and use of the albumin microbubble composition in ultrasound mediated delivery of therapeutic or diagnostic agents is also discussed.

Abstract: Provided herein are methods of reducing liver uptake in vivo of a polypeptide that specifically binds to a target comprising: (a) providing a polypeptide that specifically binds to a target; and (b) substituting at least one basic or at least one neutral amino acid residue of the native polypeptide from step (a) with an acidic amino acid residue to produce a modified polypeptide, wherein the modified polypeptide demonstrates an isoelectric point at least 0.05-0.1 pH points less than the isoelectric point of the native polypeptide. Also provided are polypeptides made using the inventive methods as well as imaging techniques that employ the methods and agents.

Abstract: A portable microbubble and drug mixing device is provided. The portable microbubble and drug mixing device comprises a flexible outer container comprising an interior chamber for accommodating a drug, and a rigid inner container within the flexible outer container and comprising an interior chamber for accommodating microbubbles. The outer container has a tensile strength at break less than or equal to approximately 15 MPa, and the inner container has a tensile strength at break greater than or equal to approximately 20 MPa and is capable of storing microbubbles at a concentration higher than or equal to approximately 5×106 microbubbles/ml. The inner container is configured to separate the microbubbles in the interior chamber of the inner container from the drug in the interior chamber of the outer container until a point of mixing when the microbubbles are released into the interior chamber of the outer container.

Abstract: A portable microbubble and drug mixing device is provided. The portable microbubble and drug mixing device comprises a flexible outer container comprising an interior chamber for accommodating a drug, and a rigid inner container within the flexible outer container and comprising an interior chamber for accommodating microbubbles. The outer container has a tensile strength at break less than or equal to approximately 15 MPa, and the inner container has a tensile strength at break greater than or equal to approximately 20 MPa and is capable of storing microbubbles at a concentration higher than or equal to approximately 5×106 microbubbles/ml. The inner container is configured to separate the microbubbles in the interior chamber of the inner container from the drug in the interior chamber of the outer container until a point of mixing when the microbubbles are released into the interior chamber of the outer container.

Abstract: The present invention relates to a method of in vivo optical imaging, of the margins around tumours, which comprises an optical imaging contrast agent. The optical imaging agents comprise conjugates of near-infrared dyes with synthetic polyethylene glycol (PEG) polymers having a molecular weight in the range 15-45 kDa. Also disclosed are optical imaging contrast agents, pharmaceutical compositions and kits.

Abstract: Provided herein are compositions and methods for lipoprotein uptake assay. These compositions and methods may be used for lipoprotein uptake assays, including high-throughput assays. The disclosed compositions and method may further be used to characterize the activity agents that inhibit or stimulate lipoprotein uptake.

Abstract: In one aspect, the present invention provides a functionalized monodisperse polylysine comprising a linear monodisperse polylysine chain comprising constituent lysine monomer residues containing appended C4-C24 polyethylene glycol groups and at least one appended fluorescent dye moiety is provided.

Abstract: Provided are in vivo imaging agents comprising muteins of hTLc having detectable binding affinity for c-Met or a domain thereof, coupled to a signal generator, and the mutein coupled to a signal generator is disposed in a pharmaceutically acceptable carrier. Also provided are diagnostic methods using in vivo imaging agents comprising muteins of hTLc having detectable binding affinity for c-Met or a domain thereof.

Abstract: Provided herein are methods of reducing liver uptake in vivo of a polypeptide that specifically binds to a target comprising: (a) providing a polypeptide that specifically binds to a target; and (b) substituting at least one basic or at least one neutral amino acid residue of the native polypeptide from step (a) with an acidic amino acid residue to produce a modified polypeptide, wherein the modified polypeptide demonstrates an isoelectric point at least 0.05-0.1 pH points less than the isoelectric point of the native polypeptide. Also provided are polypeptides made using the inventive methods as well as imaging techniques that employ the methods and agents.

Abstract: Provided herein are compositions and methods for lipoprotein uptake assay. These compositions and methods may be used for the lipoprotein uptake assays, including high-throughput assays. The disclosed compositions and method may further be used to characterize the activity agents that inhibit or stimulate lipoprotein uptake.